Premier Biomedical, Inc. CEO Letter - December, 2017

EL PASO, TX--(Marketwired - Dec 15, 2016) - Premier Biomedical, Inc. (OTCQB: BIEI)

Greetings From The CEO and Staff at Premier Biomedical!

The past year has been a difficult journey, and events during the year have caused us to re-evaluate and adjust our overall business plan. We believe the significant steps taken will result in a much brighter forecast for 2017 and beyond.

Immunotherapy and Biologics.

• Our core technology has always been centered around immunotherapy. How we differ from the principal competitors in this field is that we operate on body fluids extracorporeally (outside of the body) through the use of antibodies against disease antigens.
• The two principal areas of focus initially were Traumatic Brain Injury (TBI)/Post Traumatic Stress Disorder (PTSD) and Chronic Traumatic Encephalopathy (CTE) -- most frequently caused by repeated, non-concussive blows to the head -- and cancer. Our partners in the development of this technology were the University of Texas at El Paso (UTEP) and the William Beaumont Army Medical Center (WBAMC) at Ft. Bliss.
• Progress on our anti-cancer antibody via extended comparative testing on laboratory mice versus available competitive drugs and chemotherapy indicated a very significant advantage for our patent-pending drug.
• Superior performance of our anti-cancer antibody was acknowledged via presentation at the American Association for Cancer Research Symposia in 2014 and 2016. Most recently we were honored to receive notification that the prestigious British Journal of Cancer would publish a paper on our research in their upcoming publication.
• The next step in our development program is to humanize our patent-pending anti-cancer antibody drug. This humanization process is projected to take 4-6 months to accomplish by an outside laboratory specially equipped. The program is temporarily on hold awaiting access to the required funding to proceed.
• After the humanized anti-cancer antibody drug is available, we will engage in extensive and expensive testing on humanized laboratory animal forms and, if successful as anticipated, move to possible pre-clinical trials on humans after safety and efficacy are established.
• Completion of all of the clinical trials and pre-market development required for certification by the FDA would require extensive capital that is currently not available to the company. Our most logical approach would be to receive offers from large pharmaceutical companies which have the means and capital necessary to complete the development program. In the past, we have been contacted by two large pharmaceutical companies seeking information on our development program; therefore, we are confident that superior performance in laboratory tests followed by aggressive publication of our results will culminate in offers to license our technology for a fee.
• Our very promising initial work on finding a potential cure for PTSD/CTE is in a similar situation -- awaiting sponsorship from organizations with a vested interest in a viable cure; i.e., large sports organizations and/or the military.

Pain Management.